206 related articles for article (PubMed ID: 29454748)
1. Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors.
Chiyonobu N; Shimada S; Akiyama Y; Mogushi K; Itoh M; Akahoshi K; Matsumura S; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Arii S; Suganami T; Yamaoka S; Ogawa Y; Tanabe M; Tanaka S
Am J Pathol; 2018 May; 188(5):1213-1224. PubMed ID: 29454748
[TBL] [Abstract][Full Text] [Related]
2. Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma.
Thompson KJ; Austin RG; Nazari SS; Gersin KS; Iannitti DA; McKillop IH
Liver Int; 2018 Jun; 38(6):1074-1083. PubMed ID: 29171144
[TBL] [Abstract][Full Text] [Related]
3. Remodeling of hepatic stellate cells orchestrated the stroma-derived oxaliplatin-resistance through CCN3 paracrine in hepatocellular carcinoma.
Liao X; Bu Y; Chang F; Jia F; Song G; Xiao X; Zhang M; Ning P; Jia Q
BMC Cancer; 2019 Dec; 19(1):1192. PubMed ID: 31805888
[TBL] [Abstract][Full Text] [Related]
4. FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma.
Zhong CQ; Zhang XP; Ma N; Zhang EB; Li JJ; Jiang YB; Gao YZ; Yuan YM; Lan SQ; Xie D; Cheng SQ
Cancer Med; 2018 Jun; 7(6):2629-2640. PubMed ID: 29733540
[TBL] [Abstract][Full Text] [Related]
5. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
[No Abstract] [Full Text] [Related]
6. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
Esparza-Baquer A; Labiano I; Sharif O; Agirre-Lizaso A; Oakley F; Rodrigues PM; Zhuravleva E; O'Rourke CJ; Hijona E; Jimenez-Agüero R; Riaño I; Landa A; La Casta A; Zaki MYW; Munoz-Garrido P; Azkargorta M; Elortza F; Vogel A; Schabbauer G; Aspichueta P; Andersen JB; Knapp S; Mann DA; Bujanda L; Banales JM; Perugorria MJ
Gut; 2021 Jul; 70(7):1345-1361. PubMed ID: 32907830
[TBL] [Abstract][Full Text] [Related]
7. Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production.
Myojin Y; Hikita H; Sugiyama M; Sasaki Y; Fukumoto K; Sakane S; Makino Y; Takemura N; Yamada R; Shigekawa M; Kodama T; Sakamori R; Kobayashi S; Tatsumi T; Suemizu H; Eguchi H; Kokudo N; Mizokami M; Takehara T
Gastroenterology; 2021 Apr; 160(5):1741-1754.e16. PubMed ID: 33346004
[TBL] [Abstract][Full Text] [Related]
8. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
9. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma.
Pan L; Xiao H; Liao R; Chen Q; Peng C; Zhang Y; Mu T; Wu Z
Biomed Pharmacother; 2018 Oct; 106():68-76. PubMed ID: 29957468
[TBL] [Abstract][Full Text] [Related]
11. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
[TBL] [Abstract][Full Text] [Related]
12. Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome.
Laouirem S; Sannier A; Norkowski E; Cauchy F; Doblas S; Rautou PE; Albuquerque M; Garteiser P; Sognigbé L; Raffenne J; van Beers BE; Soubrane O; Bedossa P; Cros J; Paradis V
Oncogene; 2019 Apr; 38(16):3033-3046. PubMed ID: 30575815
[TBL] [Abstract][Full Text] [Related]
13. Cluster of differentiation 147 is a key molecule during hepatocellular carcinoma cell-hepatic stellate cell cross-talk in the rat liver.
Ma T; Wang Z; Yang Z; Chen J
Mol Med Rep; 2015 Jul; 12(1):111-8. PubMed ID: 25738354
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance and gene expression study of human hepatic stellate cells in HBV related-hepatocellular carcinoma.
Liao R; Wu H; Yi Y; Wang JX; Cai XY; He HW; Cheng YF; Zhou J; Fan J; Sun J; Qiu SJ
J Exp Clin Cancer Res; 2013 Apr; 32(1):22. PubMed ID: 23601182
[TBL] [Abstract][Full Text] [Related]
15. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma.
Ji J; Eggert T; Budhu A; Forgues M; Takai A; Dang H; Ye Q; Lee JS; Kim JH; Greten TF; Wang XW
Hepatology; 2015 Aug; 62(2):481-95. PubMed ID: 25833323
[TBL] [Abstract][Full Text] [Related]
16. CCN1/Cyr61 enhances the function of hepatic stellate cells in promoting the progression of hepatocellular carcinoma.
Li ZQ; Wu WR; Zhao C; Zhao C; Zhang XL; Yang Z; Pan J; Si WK
Int J Mol Med; 2018 Mar; 41(3):1518-1528. PubMed ID: 29286082
[TBL] [Abstract][Full Text] [Related]
17. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma.
Xie YX; Liao R; Pan L; Du CY
Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554
[TBL] [Abstract][Full Text] [Related]
18. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
[TBL] [Abstract][Full Text] [Related]
19. The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling.
Magistri P; Leonard SY; Tang CM; Chan JC; Lee TE; Sicklick JK
J Surg Res; 2014 Apr; 187(2):377-85. PubMed ID: 24439425
[TBL] [Abstract][Full Text] [Related]
20. Senescent hepatic stellate cells caused by deoxycholic acid modulates malignant behavior of hepatocellular carcinoma.
Nguyen PT; Kanno K; Pham QT; Kikuchi Y; Kakimoto M; Kobayashi T; Otani Y; Kishikawa N; Miyauchi M; Arihiro K; Ito M; Tazuma S
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3255-3268. PubMed ID: 32870388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
